Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 254

  • Filters activated: Field: Title/Abstract. Clear all
1.

Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease.

Nampoothiri RV, Duseja A, Rathi M, Agrawal S, Sachdeva N, Mehta M, Dhaliwal HS, Dhiman RK, Chawla Y.

J Clin Exp Hepatol. 2019 Jan-Feb;9(1):22-28. doi: 10.1016/j.jceh.2017.12.005. Epub 2017 Dec 30.

PMID:
30765935
2.

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.

Scheen AJ.

Diabetes Metab. 2019 Jan 29. pii: S1262-3636(19)30023-0. doi: 10.1016/j.diabet.2019.01.008. [Epub ahead of print] Review.

PMID:
30708071
3.

Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Blaner WS.

Pharmacol Ther. 2019 Jan 29. pii: S0163-7258(19)30012-9. doi: 10.1016/j.pharmthera.2019.01.006. [Epub ahead of print] Review.

PMID:
30703416
4.

Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease.

Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamicchane J, Kanth R, Gayam V.

Cureus. 2018 Nov 23;10(11):e3626. doi: 10.7759/cureus.3626.

5.

Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues.

Mu W, Cheng XF, Liu Y, Lv QZ, Liu GL, Zhang JG, Li XY.

Front Pharmacol. 2019 Jan 14;9:1566. doi: 10.3389/fphar.2018.01566. eCollection 2018. Review.

6.

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.

Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK.

Dig Dis Sci. 2019 Jan 25. doi: 10.1007/s10620-019-5477-1. [Epub ahead of print]

PMID:
30684076
7.

Effects of Hydrogen Sulfide on Carbohydrate Metabolism in Obese Type 2 Diabetic Rats.

Gheibi S, Jeddi S, Kashfi K, Ghasemi A.

Molecules. 2019 Jan 6;24(1). pii: E190. doi: 10.3390/molecules24010190.

8.

Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with type 2 diabetes mellitus.

Miyauchi S, Miyake T, Miyazaki M, Eguchi T, Niiya T, Yamamoto S, Senba H, Furukawa S, Matsuura B, Hiasa Y.

J Diabetes Investig. 2018 Dec 28. doi: 10.1111/jdi.13000. [Epub ahead of print]

9.

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.

Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y.

Diabetes Metab Syndr Obes. 2018 Nov 27;11:835-843. doi: 10.2147/DMSO.S184767. eCollection 2018.

10.

Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.

Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK.

J Gastroenterol Hepatol. 2018 Dec 14. doi: 10.1111/jgh.14577. [Epub ahead of print]

PMID:
30551263
11.

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M.

Acta Diabetol. 2018 Dec 5. doi: 10.1007/s00592-018-1266-0. [Epub ahead of print] Review.

PMID:
30519965
12.

Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.

Newfield RS, Graves CL, Newbury RO, Schwimmer JB, Proudfoot JA, Say DS, Feldstein AE.

Pediatr Diabetes. 2019 Feb;20(1):41-47. doi: 10.1111/pedi.12798. Epub 2018 Dec 9.

PMID:
30467936
13.

Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.

Finck BN.

Diabetes. 2018 Dec;67(12):2485-2493. doi: 10.2337/dbi18-0024. Review.

PMID:
30459251
14.

Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial.

Oshakbayev K, Bimbetov B, Manekenova K, Bedelbayeva G, Mustafin K, Dukenbayeva B.

Curr Med Res Opin. 2019 Jan;35(1):157-165. doi: 10.1080/03007995.2018.1547696. Epub 2018 Nov 28.

PMID:
30431378
15.

Managing diabetes and liver disease association.

Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Ahmed Aboubakr A, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S.

Arab J Gastroenterol. 2018 Dec;19(4):166-179. doi: 10.1016/j.ajg.2018.08.003. Epub 2018 Nov 9. Review.

PMID:
30420265
16.

Treatment of NASH with Antioxidant Therapy: Beneficial Effect of Red Cabbage on Type 2 Diabetic Rats.

Dal S, Van der Werf R, Walter C, Bietiger W, Seyfritz E, Mura C, Peronet C, Legrandois J, Werner D, Ennahar S, Digel F, Elisa MP, Pinget M, Jeandidier N, Marchioni E, Sigrist S.

Oxid Med Cell Longev. 2018 Sep 30;2018:7019573. doi: 10.1155/2018/7019573. eCollection 2018.

17.

Polychlorinated biphenyl exposures differentially regulate hepatic metabolism and pancreatic function: Implications for nonalcoholic steatohepatitis and diabetes.

Shi H, Jan J, Hardesty JE, Falkner KC, Prough RA, Balamurugan AN, Mokshagundam SP, Chari ST, Cave MC.

Toxicol Appl Pharmacol. 2019 Jan 15;363:22-33. doi: 10.1016/j.taap.2018.10.011. Epub 2018 Oct 9.

PMID:
30312631
18.

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K.

J Investig Med. 2019 Feb;67(2):303-311. doi: 10.1136/jim-2018-000864. Epub 2018 Oct 10.

PMID:
30309884
19.

A Young Adult Patient with Nonalcoholic Steatohepatitis Developed Severe Gastroesophageal Varices Associated with Severe Obesity and Diabetes Mellitus.

Honma Y, Sumida K, Ogino N, Kusanaga M, Minami S, Kumei S, Matsuoka H, Watanabe T, Hiura M, Abe S, Shibata M, Harada M.

Case Rep Gastroenterol. 2018 Aug 23;12(2):487-496. doi: 10.1159/000492423. eCollection 2018 May-Aug.

20.

Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.

Cholankeril R, Patel V, Perumpail BJ, Yoo ER, Iqbal U, Sallam S, Shah ND, Kwong W, Kim D, Ahmed A.

Diseases. 2018 Oct 3;6(4). pii: E93. doi: 10.3390/diseases6040093. Review.

Supplemental Content

Loading ...
Support Center